← Leaderboards
Ahmed Chadli
Augusta University
$3,666,836
Attributed
$3,666,836
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $941.4K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,666,836 · 3
By mechanism
R01$3,666,836 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMolecular ChaperonesProteinsCancer CellCellsInfiltrationInnovationMalignant Breast NeoplasmCancer TherapyImmuneImmune ToleranceAntitumor ResponseImmunotherapeutic AgentImmunotherapyImmune Checkpoint BlockadeCd8-Positive T-LymphocytesClientBreast Cancer ModelDesignHeat-Shock Proteins 90Binding SitesBiochemicalAffectBreast Cancer Patient
Grant awards (10)
Suppressing the Co-chaperone UNC45A reprograms the immunosuppressive tumor microenvironment to fight Cancer$587,524
R01 · FY2025 · CA · contact PI
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance$352,275
R01 · FY2025 · CA · contact PI
Suppressing the Co-chaperone UNC45A reprograms the immunosuppressive tumor microenvironment to fight Cancer$606,697
R01 · FY2024 · CA · contact PI
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance$334,662
R01 · FY2024 · CA · contact PI
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance$345,230
R01 · FY2023 · CA · contact PI
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance$345,230
R01 · FY2022 · CA · contact PI
A novel therapeutic strategy to eradicate breast cancer through Hsp90 inhibition and reduced immune tolerance$352,275
R01 · FY2021 · CA · contact PI
Targeting the core components of the Hsp90 chaperoning machine$255,825
R01 · FY2014 · GM · contact PI
Targeting the core components of the Hsp90 chaperoning machine$246,871
R01 · FY2013 · GM · contact PI
Targeting the core components of the Hsp90 chaperoning machine$240,247
R01 · FY2012 · GM · contact PI